AIRS Medical appoints Tim Murdoch as Chief Commercial Officer. AIRS Medical appoints Tim Murdoch as Chief Commercial Officer to accelerate its next phase of global growth. * September 24, 2026 Veteran Adobe, Salesforce and IntegriChain executive joins the TA Associates-backed MRI intelligence company to scale its global commercial organization SEOUL, South Korea and CHICAGO, Ill. - September 24, 2026 - AIRS Medical, a global AI medical imaging company advancing MRI intelligence, today announced the appointment of Tim Murdoch as Chief Commercial Officer (CCO). Murdoch will lead AIRS Medical's commercial organization, with responsibility for go-to-market execution, the partner ecosystem, and scaling the company's commercial team globally. The appointment comes at a moment of significant momentum for AIRS Medical. The company's solutions are cleared or approved in more than 40 countries and deployed across more than 1,700 healthcare institutions, and earlier this year the company announced a strategic growth investment from TA Associates to accelerate its next phase of expansion. Murdoch brings more than 25 years of experience scaling enterprise SaaS and data-driven businesses across healthcare, life sciences and other complex industries, with executive leadership positions at Adobe, Salesforce, SAP, PTC and, most recently, IntegriChain. "MRI is becoming an intelligence platform, and our next stage is about scaling enterprise execution to match the technology," said Jason Park, Chief Executive Officer of AIRS Medical. "Tim has built and led commercial organizations at some of the most demanding enterprise technology companies in the world, and he understands what world-class go-to-market looks like in healthcare. With the foundation we have built and the backing of TA Associates, this is the right moment to bring in a leader of his experience to build our global commercial engine." Before joining AIRS Medical, Murdoch served as Chief Commercial Officer of IntegriChain, where he led the global commercial organization across sales, marketing, strategic accounts, commercial operations and industry solutions, and drove a comprehensive enterprise go-to-market transformation. Previously, he served as General Manager of Healthcare & Life Sciences at Adobe, with full P&L responsibility for the vertical; during his tenure, the business grew from approximately $35 million to more than $450 million in annual recurring revenue, and he helped launch Adobe Experience Cloud for Healthcare. His earlier career includes global strategic-account leadership at Salesforce, enterprise software leadership at SAP, and sales and regional leadership roles at PTC. "AIRS Medical has built extraordinary AI technology with the potential to reshape medical imaging. What convinced me to join is that this isn't just a compelling technology story - it's a proven platform delivering real operational and economic value, with enormous opportunity still ahead," said Tim Murdoch. "Our next chapter is about bringing that innovation to customers around the world, expanding our strategic partnerships and building a world-class commercial organization capable of delivering sustained global growth." AIRS Medical continues to expand its AI-powered MRI portfolio as healthcare organizations seek to address growing imaging demand, optimize capital investment and improve access to advanced diagnostics. SwiftMR(R) helps imaging organizations improve MRI performance across diverse scanner fleets, while SwiftSight(R) extends that foundation into quantitative and longitudinal imaging intelligence. About AIRS Medical. AIRS Medical is a global AI medical imaging company transforming MRI through deep learning. Its solutions, SwiftMR(R) and SwiftSight(R), are deployed at leading health systems and imaging networks worldwide. SwiftMR(R) is FDA-cleared, CE-marked under MDR, and approved by Korea's MFDS, Japan's PMDA, and other regulatory authorities across 40+ countries. Learn more at airsmed.com. Media contact. Cynthia Ruffino Vice President, Marketing Email: [email protected]

IntegriChain leaders to speak at Informa's fall 2026 MDRP, GTN, and Trade & Channel summits. Sep 22, 2026, 08:00 ET Company experts will deliver sessions on government pricing policy, 340B, gross-to-net strategy, and trade and distribution trends across three premier industry events this fall PHILADELPHIA, Sept. 22, 2026 /PRNewswire/ - IntegriChain, the leading provider of pharma net revenue optimization technology, data, and consulting for the life sciences industry, today announced that its subject matter experts will present at three of Informa Connect's flagship fall conferences: the Medicaid Drug Rebate Program (MDRP) Summit, the Pharma/Biotech Gross-to-Net (GTN) Summit, and Trade & Channel Strategies. Across the three events, IntegriChain leaders will share insights on government pricing and contracting, 340B, gross-to-net forecasting, and the future of pharmaceutical distribution and access. "Government pricing, 340B, gross-to-net, and trade and channel strategy are more interconnected and more consequential than ever for our clients," said Jeff Baab, Partner, Advisory Services with IntegriChain "These conferences give our team the opportunity to bring real-world perspective from the hundreds of manufacturers we support directly to the industry." Baab, Willis Speaks on Evolving Contracting Environment At the Medicaid Drug Rebate Program (MDRP) Summit 2026, taking place October 5-7, 2026, at the Fairmont Chicago Millennium Park in Chicago, IL, Jeff Baab, Partner, Advisory Services at IntegriChain, will present "Updates on Landscape of Government Pricing and Contracting" on Wednesday, October 7, at 9:40 AM. Baab will share his perspective on the evolving government pricing and contracting environment, drawing on his extensive experience advising manufacturers on gross-to-net, contracting, and market access across both commercial and government channels. 340B industry expert Clay Willis, Partner, Advisory Services at IntegriChain will also present "340B Movement to Have All 340B Claims in One System of Record" on Wednesday, October 7 at 10:50 AM, while also offering an update on the recent 340B events such as the the rebate model pilot program #2, contract and in-house pharmacy policies, patient definition, plus other activities occurring in the market. At the Pharma/Biotech Gross-to-Net (GTN) Summit 2026, taking place November 16-18, 2026, at the Hilton at Penn's Landing in Philadelphia, PA, two IntegriChain leaders will take the stage to share perspectives on the issues shaping gross-to-net strategy. On Monday, November 16, at 4:30 PM, Jennifer Sharpe, Vice President, Gross-to-Net Consulting and Facilitator of the Revenue Analytics Collaborative at IntegriChain, will host and moderate "Hot Topic Roundtable Discussions: Sponsored by IntegriChain's Revenue Analytics Collaborative (RAC)" for RAC members. The session will bring together participants from the 800+ member industry peer network Sharpe co-founded to discuss the topics shaping GTN strategy today. On Tuesday, November 17, at 10:55 AM, Walt Worsham, Managing Director at IntegriChain, will present "Drug Pricing Policy & Regulatory Landscape Updates," offering an update on the drug pricing policy and regulatory developments most relevant to gross-to-net forecasting, accruals, and contracting strategy. At Trade & Channel Strategies 2026, taking place December 8-10, 2026, at the W Hotel in Philadelphia, PA, Bill Roth, Senior Vice President and Managing Partner, Consulting and Advisory at IntegriChain, will deliver a keynote address on the state of the channel. His remarks will examine the disruption facing today's pharmacy and distribution landscape, from reimbursement pressure at national retail chains to the downstream effects on specialty and general medicine brands. For more insights on government pricing, 340B, and gross-to-net strategy from IntegriChain's team, visit www.integrichain.com or follow IntegriChain on LinkedIn. About IntegriChain IntegriChain delivers biopharma's only comprehensive data-driven commercialization platform from strategy to operational execution connecting the commercial, financial, and operational dimensions of drug access and profitability. Our ICyte(R) platform integrates technology, data, consulting, and managed services to unify critical workflows replacing manual processes with integrated analytics and precision controls. Biopharma relies on IntegriChain to optimize patient access and net revenue performance, reduce leakage, and strengthen compliance, ensuring every life-changing therapy reaches patients with speed, affordability, and sustainability. Backed by Nordic Capital, a leading sector-specialized private equity investor with a broad portfolio in healthcare and technology. IntegriChain is headquartered in Philadelphia, PA, with a location in Pune, India. For more information, visit www.integrichain.com or follow us on LinkedIn. Media Contact Brandy Jensen, Senior Director Marketing, IntegriChain SOURCE IntegriChain, Inc.

IntegriChain has launched a beta version of its conversational AI assistant with select biopharma partners, aiming to modernise commercial data decision-making. The beta integrates data management, analytics and execution into a single AI-ready environment, focusing on government price reporting, Medicaid rebate adjudication, channel management and specialty commercial excellence. The company has established four Domain Teams to train and validate AI resources across these areas. The AI assistant will respond to natural-language queries and provide root-cause analysis beyond traditional dashboards, with general availability planned for later this year. Built on IntegriChain's ICyte cloud-native platform, the system prioritises explainability and regulatory compliance. To support platform delivery, IntegriChain has appointed John Ristuccia as Senior Vice President of Professional Services and Support.